pembrolizumab
merck
['melanoma']
 upenn study got similar path response numbers w 1 dose neoadj. don t think we need 3 doses. exciting to think about a future of single dose combo io pre-surgery and only treating w adjuvant rx if patients don t have pcr. #melanoma #esmo22 
Immunotherapy of Cancer • Melanoma • Phase I Clinical Trials • Targeted Therapies for Cancer • Lab: @ImmunoTiil • Disclosures at https://t.co/mcWOaTaiZn…